AnGes MG Announces Results of Phase II Clinical Trials of HGF Gene Medicine.Tokyo, Japan, June 7, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - AnGes MG announced on June 5 the results of its phase II clinical trials of AMG0001, HGF HGF, n See glucagon. (Hepatocyte Growth Factor Hepatocyte growth factor/scatter factor (HGF/SF) is a paracrine cellular growth, motility and morphogenic factor. It is secreted by mesenchymal cells and targets and acts primarily upon epithelial cells and endothelial cells, but also acts on haemopoietic progenitor cells. ) gene medicine. Conducted in the US and intended to verify the efficacy and safety of AMG0001, the trials covered 104 patients with severe peripheral arterial disease. The results indicated that the administration of AMG0001 contributes to improving hemodynamics hemodynamics /he·mo·dy·nam·ics/ (-di-nam´iks) the study of the movements of blood and of the forces concerned.hemodynam´ic he·mo·dy·nam·ics n. . The drug tolerability proved to be good, and there were no safety problems. Details of the trials were presented at the meeting of the Society for Vascular Medicine and Biology held in Philadelphia on June 3. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion